Literature DB >> 2563231

Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunction.

G K Thaker1, J A Nguyen, C A Tamminga.   

Abstract

In mammals, GABAergic projections from the substantia nigra reticulata to the superior colliculus provide tonic inhibition to tectal neurons involved in the generation of saccades. Dysfunction of this pathway has been shown to produce saccadic "distractibility" in the experimental monkey. In two oculomotor paradigms, control of saccadic eye movements was tested in chronic schizophrenic patients with (n = 18) and without (n = 16) tardive dyskinesia (TD) and normal controls (n = 8). The three groups were matched by mean age; the TD and non-TD patient groups had similar duration of illness, benztropine and chlorpromazine equivalent doses and educational levels. A twofold increase in saccadic distractibility was observed in TD compared to non-TD schizophrenic patients, and both patient groups demonstrated a greater saccadic distractibility than normals. Furthermore, schizophrenic patients (both with and without TD) showed significantly increased latency for "volitional" saccades compared to the normal controls. These findings may provide further evidence for basal ganglia GABA dysfunction in tardive dyskinesia, as well as demonstrate oculomotor abnormalities in schizophrenic individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563231     DOI: 10.1016/0006-3223(89)90146-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations.

Authors:  Deborah L Levy; Nancy R Mendell; Philip S Holzman
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

2.  More GABA, less distraction: a neurochemical predictor of motor decision speed.

Authors:  Petroc Sumner; Richard A E Edden; Aline Bompas; C John Evans; Krish D Singh
Journal:  Nat Neurosci       Date:  2010-05-30       Impact factor: 24.884

3.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

4.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

Review 5.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

6.  Improved antisaccade performance with risperidone in schizophrenia.

Authors:  J G Burke; M A Reveley
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

7.  Electrophysiological studies of the GABAA receptor ligand, 4-PIOL, on cultured hippocampal neurones.

Authors:  U Kristiansen; J D Lambert; E Falch; P Krogsgaard-Larsen
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  Antisaccades and remembered saccades in Parkinson's disease.

Authors:  C J Lueck; S Tanyeri; T J Crawford; L Henderson; C Kennard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

9.  Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Shrinivas K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

Review 10.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.